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Abstract
Background: Pathological brain iron deposition has been implicated as a source of neurotoxic
reactive oxygen species in Alzheimer (AD) and Parkinson diseases (PD). Iron metabolism is
associated with the gene hemochromatosis (HFE  Human genome nomenclature committee
ID:4886), and mutations in HFE are a cause of the iron mismetabolism disease, hemochromatosis.
Several reports have tested the association of HFE variants with neurodegenerative diseases, such
as AD and PD with conflicting results.
Methods: Genotypes were analysed for the two most common variants of HFE in a series of 130
AD, 55 Mild Cognitive Impairment (MCI) and 132 PD patients. Additionally, a series of 115 healthy
age-matched controls was also screened.
Results: A statistically significant association was found in the PD group when compared to
controls, showing that the presence of the C282Y variant allele may confer higher risk for
developing the disease.
Conclusion: Taken together these results suggest that the common variants in HFE may be a risk
factor for PD, but not for AD in the Portuguese population.
Background
Classic Hemochromatosis is an autosomal recessive disor-
der that is associated with a deregulation of the iron
metabolism [1]. Clinical features often include cirrhosis
of the liver, diabetes, hypermelanotic pigmentation of the
skin, and heart failure [2]. Hemochromatosis is most
often caused by mutations in the gene HFE on chromo-
some 6p21.3. The most common mutation, C282Y, was
initially found in a subset of patients with hereditary
hemochromatosis, in a total of 83% of all individuals. A
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second mutation, H63D, was also described, although the
clinical effects of this modification are clearly more lim-
ited. However, about 1 to 2 percent of individuals with
compound heterozygous HFE mutations appear to be at
risk for hemochromatosis [3].
Alzheimer's disease is the most common late-onset neuro-
degenerative disorder. While several studies have tried to
unveil the precise mechanisms underlying the etiology of
typical sporadic AD, these remain largely unknown.
Nonetheless, several studies have reported that oxidative
stress may be implicated in the pathogenesis of this con-
dition [4,5]. Oxidative damage in AD brain may be due, at
least partially, to the increased deposition of redox-active
iron, which is an important generator of reactive oxygen
species (ROS) [6]. HFE mutations have been associated
with different stages of dementia (Braak stages) and
increased oxidative stress, thus a study including MCI
patients is of relevance [7]. However this remains only a
speculation, as the mechanisms governing pathological
brain iron deposition in AD are still unidentified.
Parkinson's disease is the second most common form of
neurodegenerative disease, characterized clinically by rest-
ing tremor, muscular rigidity, bradykinesia, and postural
instability. Post-mortem examinations of PD brains and
magnetic resonance imaging of PD patients have revealed
increased iron contents in the substantia nigra [8]. The
cause for this deposition is unclear; however it has been
speculated to result in overproduction of free radicals,
which in turn, may cause lipid peroxidation, protein and
nucleic acid oxidation [9].
Previous studies assessing the effect of HFE variants on the
onset of PD and AD have been contradictory [7,10-12].
Thus, to ascertain if HFE mutations are a risk factor for the
development of these diseases, we conducted a genetic
screening for the most common HFE mutations in two
series of patients and in a healthy control group.
Methods
Subjects
A total of 428 individuals were screened for two muta-
tions in the HFE gene: C282Y (rs1800562) and H63D
(rs1799945).
The first series of patients integrated AD and MCI patients.
The diagnosis of probable Alzheimer's disease was made
in accordance with criteria defined by the Diagnostic and
Statistical Manual, revision 4 (DSM-IV) [13] and the
guidelines of the National Institute of Neurological Disor-
ders and Stroke, and the Alzheimer's Disease and Related
Disorders Association (NINCDS-ADRDA) [14]. All partic-
ipants were assessed with the Mini Mental-State Examina-
tion (MMSE) [15] and the Clinical Dementia Rating
(CDR) [16] scales. The diagnosis of MCI was made in
accordance with criteria defined by Petersen [17]. AD
patients were selected from a consecutive clinic case series
of those who gave permission for sampling (over 90% of
cases consent for blood sampling), collected by neurolo-
gists at the University of Coimbra Hospital. Selection was
performed to include patients with a negative familial his-
tory and a late age at onset for the disease (≥ 65 years).
This group included 130 patients (79 females and 51
males) with mean ages of 75 ± 5 years and mean age at
onset of 71,5 ± 4,9 years. In this series were also included
55 MCI patients (32 females and 23 males) with mean
ages of 69,5 ± 9,6 and mean age at onset of 67,5 ± 9,4
years.
A total of 132 PD patients were selected according to the
United Kingdom Parkinson's Disease Society Brain Bank
Clinical Diagnostic Criteria (UK PDS Brain Bank) [18].
Patients comprised a consecutive clinic based cohort (over
90% of cases consent for blood sampling), diagnosed by
a movement disorder specialist at the movement disorder
clinic of the University of Coimbra Hospital. This series
included 62 males and 70 females, with mean of ages of
66,7 ± 10,7 years, and mean age at onset of 57,2 ± 12,0
years. From these, 28 patients presented with a positive
family history for PD, while the remaining 104 showed no
evidence of family history for PD or any form of parkin-
sonism.
The control group included 115 healthy controls with a
mean age of 70,7 ± 10,3 years, 38 males and 77 females.
All subjects were examined by a neurologist and were free
of any clinical signs or symptoms of neurodegeneration.
This group comprised mainly spouses of patients and car-
egivers that were accompanying patients to the clinic.
All individuals included in this study are Caucasian with
an apparent Portuguese ancestry. The study was submitted
to the Ethics board of the University Hospital of Coimbra
and all the subjects involved gave their informed consent.
Genotyping
Genomic DNA was isolated from whole blood by means
of standard procedures and the samples were genotyped
for the HFE  mutations C282Y and H63D using the
polymerase chain reaction (PCR) technique with subse-
quent restriction and gel electrophoresis, as previously
described [12]. Similarly, APOE genotypes were assessed
by a PCR-based methodology, as previously described
[19].
Statistical analysis
Observed genotype distributions were compared with
those expected by cross-tabulation and analyzed using
Chi-square and Fisher Exact-tests. Means of quantitativeBMC Neurology 2006, 6:24 http://www.biomedcentral.com/1471-2377/6/24
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variables were compared using Student's t-test. Kaplan-
Meier (KM) survival analysis was used to analyze the
effects of the HFE mutations on the age of AD, PD and
MCI onset. The log-rank test was employed to determine
whether genotype-specific survival functions were signifi-
cantly different from one another. All tests were inter-
preted at the 0,05 level of significance. All statistical
analyses were performed with the SPSS package, version
10.0 (SPSS, Chicago, IL, USA).
Results
To test the association between the presence of the C282Y
and H63D mutations and the development of AD or PD,
we screened these series of patients and a series of healthy
controls. The genotypes in these cohorts were at or near
Hardy-Weinberg equilibrium.
There was no significant difference in genotype or allele
frequencies in the AD or MCI groups, compared to con-
trols. Analysis of the genotypes in the PD series revealed a
significant overrepresentation of 282Y carriers and of the
282Y allele compared to controls (p = 0.01) (Tables 1 and
2). There was a statistically significant difference in the
number of 282Y carriers between the AD and PD groups
(p = 0.01). No other associations were found in any of the
series we studied (Tables 1 and 2).
The outcome of the genetic mutations studied may also
affect the age at onset of the studied disorders. Therefore
we used Kaplan-Meier survival curves to determine this
outcome. We failed to find any association between the
mutations studied and the age at onset of PD, AD or MCI,
as can be seen in Figures 1, 2 and 3.
The effect of many gene polymorphisms may be altered by
the presence or absence of the ApoE4 allele. Stratifying
based on E4 status did not reveal any significant differ-
ences in C282Y and H63D mutation frequency in AD
patients compared to controls (Table 3).
We did not observe any differences between groups when
the data were analysed according to gender (data not
shown).
Discussion
Our results suggest that C282Y and H63D variants of HFE
do not contribute significantly to the risk of developing
AD or MCI, in the Portuguese population. These data are
consistent with previous studies [12,21] but contradictory
to others such as those by Moalem and colleagues who
reported that HFE mutations predisposed to familial AD
in ApoE E4 negative males [22] and data from Pulliam et
al. that suggested that HFE  mutations were associated
with increased oxidative stress and Braak AD stage [7]. The
latter study was the primary impetus behind us studying
these variants in MCI, a recognised prodromal stage of
AD. Other studies demonstrated the potential association
between the mutant H63D allele and the age at onset of
AD [11,23]. Sampietro and colleagues reported that in an
Italian sample, where the C282Y mutation is very uncom-
mon, onset of AD occurred about 5 years earlier in sub-
jects carrying one or more copies of the H63D mutation,
independently of gender. In patients under 70 years at dis-
ease onset, the incidence of the H63D mutation was five
times higher than in those over 80 years at onset of the
disease [24]. These studies suggest that not just homozy-
gosity but also heterozygosity for the main HFE mutations
may influence AD pathogenesis. In our sample no associ-
ation between the studied mutations (in homozygosity or
heterozygosity) and the age at onset of AD, MCI or PD was
found.
The lack of association between genetic variability in HFE
and AD in the current study may be related to one or more
of several factors: first, the present results may represent a
false negative finding, driven in part by the low sample
numbers; second, the role of HFE variants in risk for dis-
ease may vary between different populations (ie genetic
background); third, as discussed below, the variants stud-
ied here may not be disease causing, but in linkage dise-
quilibrium with disease causing mutations, thus
discordant results will be seen in different populations.
The data presented here show a significant increase of the
prevalence of 282Y carriers in the PD cohort compared to
controls. A previous study examining the relationship
between HFE variants and PD reported an opposite effect
Table 1: Genotype frequencies for HFE mutations in controls, AD, PD and MCI patients
C282Y p H63D p
AA GA GG GG CG CC
Controls (n = 
115)
0 5 (4.3%) 110 (95.7%) 2 (1.7%) 39 (33.9%) 74 (64.3%)
AD (n = 130) 0 6 (4.6%) 124 (95.4%) 0.92 4 (3.1%) 41 (31.5%) 85 (65.4%) 0.76
MCI (n = 55) 0 3 (5.5%) 52 (94.5%) 0.75 3 (5.6%) 18 (33.3%) 33 (61.1%) 0.39
PD (n = 132) 0 18 (13.6%) 114 (86.4%) 0.01* 5 (3.8%) 38 (28.8%) 89 (67.4%) 0.47
*p < 0.05 (Statistically significant)BMC Neurology 2006, 6:24 http://www.biomedcentral.com/1471-2377/6/24
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to the data presented here: the authors presented data sug-
gesting that individuals with C282Y mutation have a
decreased risk of developing PD [11], in contrast an addi-
tional study suggests no role of HFE variants in risk for PD
[20] and recent work describes a positive relationship
between the 282Y variant and PD risk, consistent with the
data presented in the current study [10].
The discordant results may be explained by several factors:
first, the results of the current study and those of Dekker
and colleagues represent false positive findings; second,
the results of Buchannan and colleagues represent false
positive findings; third, 282Y is not a causal variant but is
in linkage disequilibrium with another variant that under-
lies disease risk. The degree and direction of a disease
association when genotyping what is in effect a tagging
SNP, are both sensitive to the structure and content of a
given block of linkage disequilibrium; these factors are
both potentially different between populations. The
observation that the 282Y allele is overrepresented in the
PD cohort compared to the AD cohort demonstrates
explicitly the main findings of this paper; that this variant
may infer risk for PD, but not AD in the Portuguese pop-
ulation. While it is tempting to speculate that differences
in iron handling may differentiate the molecular under-
pinnings of these two disorders, the current data is too far
removed from this mechanistically and too preliminary to
make this a convincing argument. The infrequency of
C282Y mutations obviously limits the statistical power of
this analysis, thus, studies in larger samples from diverse
populations are needed to clarify the relationship
between variability in HFE and PD The small number of
individuals in this study makes an ultimate assessment of
the biological and genetic significance of these data clearly
Table 2: Allelic frequencies for HFE mutations in controls, AD, PD and MCI patients
C282Y p H63D p
AG GC
Controls (n = 115) 5 (2.2%) 225 (97.8%) 43 (18.7%) 187 (81.3%)
AD (n = 130) 6 (2.3%) 254 (97.7%) 0.92 49 (18.8%) 211 (81.2%) 0.97
MCI (n = 55) 3 (2.7%) 107 (97.3%) 0.75 24 (22.2%) 84 (77.8%) 0.45
PD (n = 132) 18 (6.8%) 246 (93.2%) 0.01* 48 (18.2%) 216 (81.8%) 0.88
*p < 0.05 (Statistically significant)
Kaplan-Meier survival curves indicating the effect of H63D and C282Y mutations on age of AD onset Figure 1
Kaplan-Meier survival curves indicating the effect of H63D and C282Y mutations on age of AD onset. (A) There 
are no statistically significant differences in the age at onset of AD between wild type, heterozygous and homozygous patients 
for H63D mutation (χ2(2df) = 0.14, P = 0.93). (B) There are no statistically significant differences in the age at onset of the dis-
ease between wild type, heterozygous and homozygous patients for C282Y mutation (χ2(1df) = 3.08, P = 0.08).BMC Neurology 2006, 6:24 http://www.biomedcentral.com/1471-2377/6/24
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impossible. Thus we have analysed all previous studies
published so far on this subject, in order to perform a
meta-analysis of the data, and hopefully shed some light
on these mechanisms.
Regarding AD, a total of five studies has been published
aiming to find an association of these HFE mutations with
the disease. No statistically significant differences were
Kaplan-Meier survival curves indicating the effect of H63D (A) and C282Y (B) mutations on age of MCI onset Figure 2
Kaplan-Meier survival curves indicating the effect of H63D (A) and C282Y (B) mutations on age of MCI onset. 
There are no statistically significant differences in the age at onset of MCI between wild type, heterozygous and homozygous 
patients for H63D mutation (χ2(2df) = 0.04, P = 0.98). (B) There are no statistically significant differences in the age at onset of 
MCI between wild type, heterozygous and homozygous patients for C282Y mutation (χ2(1df) = 0.10, P = 0.76).
Kaplan-Meier survival curves indicating the effect of H63D and C282Y mutations on age of PD onset Figure 3
Kaplan-Meier survival curves indicating the effect of H63D and C282Y mutations on age of PD onset. (A) There 
are no statistically significant differences in the age at onset of PD between wild type, heterozygous and homozygous patients 
for H63D mutation (χ2(2df) = 2.4, P = 0.30). (B) There are no statistically significant differences in the age at onset of PD 
between wild type, heterozygous and homozygous patients for C282Y mutation (χ2(1df) = 1.66, P = 0.20).BMC Neurology 2006, 6:24 http://www.biomedcentral.com/1471-2377/6/24
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found in any of the studies. The combined data set can be
observed in Tables 4 and 5.
As for PD, two studies have described a positive associa-
tion between the C282Y variation and the disease [10,11],
as can be seen in Tables 6 and 7. However, the study of
Buchanan et al. includes siblings in the control group,
which may have biased the results. As for the work of
Dekker et al., the association was only evident in one of
the studied cohorts: the Rotterdam study.
When looking at all the results published so far, there is
no statistically significant association between any of the
variations and the development of any of the diseases
(Tables 4,5,67).
Conclusion
In conclusion we present data that suggests genetic varia-
bility in HFE may be a risk factor for PD. The rarity of HFE
282Y limits the statistical power of this analysis, thus stud-
ies in larger samples and in diverse cohorts are needed to
make clarify the relation between variability in HFE and
PD.
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Table 7: Meta-analysis of the H63D variation in the two published studies regarding Parkinson's disease
PD H63D
Patients Controls
Author wt/wt wt/mut mut/mut wt/wt wt/mut mut/mut p
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Dekker, M. [10] 44 (73.3%) 16 (26.7%) 0 2185 (75%) 661 (22.7%) 68 (2.3%)
Borie, C. [20] 42 (63.6%) 23 (34.8%) 1 (1.5%) 39 (66.1%) 20 (33.9%) 0
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